--- schema_version: "secwatch.filing_event.v1" accession: "0001493152-26-029512" form_type: "8-K" ticker: "PVCT" cik: "0000315545" company_name: "PROVECTUS BIOPHARMACEUTICALS, INC." filed_at: "2026-06-22T13:00:29+00:00" generated_at: "2026-06-22T13:01:16.450747+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.5 calibrated_materiality_score: 0.5 confidence: "high" source: SEC EDGAR --- # Provectus shareholders elect directors, approve reverse stock split authorization ## Summary - Directors elected: Webster Bailey, John Lacey III, Ed Pershing, Dominic Rodrigues. - Advisory vote on executive compensation passed with 190M for vs 17M against. - Ratification of CBIZ CPAs as auditor for 2026 passed with 330M for. - Reverse stock split authorized (ratio 1:10 to 1:50) with 315M for, 24M against. - Authorized share decrease (by same ratio) approved with 312M for, 22M against. ## SEC filing metadata - accession: 0001493152-26-029512 - form_type: 8-K - ticker: PVCT - cik: 0000315545 - company_name: PROVECTUS BIOPHARMACEUTICALS, INC. - filed_at: 2026-06-22T13:00:29+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.5 - calibrated_materiality_score: 0.5 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315226029512/0001493152-26-029512-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315226029512/form8-k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001493152-26-029512 - JSON: https://secwatch.observer/filing/0001493152-26-029512.json - Plain text: https://secwatch.observer/filing/0001493152-26-029512.txt ## Key facts - Shareholder Votes PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Election of Directors at the 2026-06-18 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-18 source text: Proposal 1 . The Company’s stockholders elected the following directors for a term of one-year, consistent with the recommendation of the Company’s board of directors (the “Board”). There were 131,619,889 broker non-votes with respect to the proposal. Name of Candidate Number of Votes For Withhold Authority Webster Bailey 191,823,174 16,387,830 John Lacey, III, M.D. 191,947,635 16,263,369 Ed Pershing, CPA 197,553,672 10,657,332 Dominic Rodrigues 192,036,957 16,174,047 evidence_url: https://www.sec.gov/Archives/edgar/data/315545/000149315226029512/0001493152-26-029512-index.htm - Shareholder Votes PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Ratification of selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for 2026 at the 2026-06-18 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-18 source text: Proposal 3 . The Company’s stockholders ratified the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for 2026, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 329,742,597 Against 7,6914,122 Abstention 2,474,174 evidence_url: https://www.sec.gov/Archives/edgar/data/315545/000149315226029512/0001493152-26-029512-index.htm - Shareholder Votes PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2026-06-18 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-18 source text: Proposal 2 . The Company’s stockholders approved the advisory vote on the compensation of the Company’s named executive officers, consistent with the Board’s recommendation. There were 131,619,889 broker non-votes with respect to the proposal. Number of Votes For 190,162,705 Against 16,667,960 Abstention 1,380,339 evidence_url: https://www.sec.gov/Archives/edgar/data/315545/000149315226029512/0001493152-26-029512-index.htm - Shareholder Votes PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Authorization to amend Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-10 and 1-for-50 at the 2026-06-18 meeting. - Proposal: reverse split - Outcome: passed - Meeting: 2026-06-18 source text: Proposal 4 . The Company’s stockholders authorized the Board to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50, where the ratio would be determined by the Board at its discretion, and to make corresponding amendments to the Certificates of Designation to provide for the proportional adjustment of certain terms upon a reverse stock split, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 315,344,309 Against 23,622,833 Abstention 863,751 evidence_url: https://www.sec.gov/Archives/edgar/data/315545/000149315226029512/0001493152-26-029512-index.htm - Shareholder Votes PROVECTUS BIOPHARMACEUTICALS, INC. shareholders approved Authorization to amend Certificate of Incorporation to decrease authorized shares of common and preferred stock by the reverse stock split ratio at the 2026-06-18 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2026-06-18 source text: Proposal 5 . The Company’s stockholders authorized the Board, given the Company’s stockholders’ approval of Proposal 4, to amend the Company’s Certificate of Incorporation, as amended by the Certificates of Designation, to decrease the number of authorized shares of the Company’s common stock and preferred stock by the same reverse stock split ratio determined by the Board, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 311,771,119 Against 22,227,876 Abstention 5,831,898 evidence_url: https://www.sec.gov/Archives/edgar/data/315545/000149315226029512/0001493152-26-029512-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.